Nutriband Inc.
ORLANDO, FL / ACCESSWIRE / June 20, 2024 / Nutriband Inc.("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) provides an update on its Aversa Fentanyl product development program to shareholders as it aims to complete scale-up of the commercial manufacturing process and move towards the single Phase 1 human abuse potential study prior to NDA filing.
- As previously reported, the Company with its partner Kindeva Drug Delivery completed the feasibility agreement and entered into a commercial development and clinical supply agreement to manufacture product for the human abuse potential clinical study in support of a New Drug Application (NDA) to be submitted to FDA. The feasibility agreement was focused on adapting Kindeva's commercial transdermal manufacturing process to incorporate AVERSA™ abuse deterrent transdermal technology.
- Nutriband is currently working with its partner Kindeva Drug Delivery to develop the commercial scale manufacturing process for the final product which will incorporate Nutriband's AVERSA™ abuse-deterrent transdermal technology into Kindeva's FDA-approved transdermal fentanyl patch system.
- Recently, Kindeva Drug Delivery completed the validation of the aversive agent cleaning analytical methods required to allow work with the aversive agents, denatonium benzoate and capsaicin, on the commercial manufacturing line.
- Once the final commercial product manufacturing process is completed, Nutriband intends to file an IND with the FDA and perform the pivotal laboratory and clinical evaluations to demonstrate the abuse-deterrent properties of AVERSA Fentanyl, in compliance with FDA Guidance.
- Nutriband will file an Investigational New Drug (IND) application with the FDA prior to conducting the single Phase 1 human abuse potential clinical study required for its NDA. The IND will include the chemistry, manufacturing, and controls (CMC) information for the commercial product as well as the clinical study protocol for the human abuse potential study.
- No Phase 2 or phase 3 Clinical Trials are required prior to submitting for approval.
- AVERSA(TM) Fentanyl is estimated to have the potential to reach peak annual US sales of $80 million to $200 million, according to a market analysis report from Health Advances(1).
The pivotal laboratory assessment to be conducted is a series of in vitro manipulation and extraction studies designed to determine if the potentially abuse-deterrent properties of the product can be defeated or compromised based on physical and chemical manipulation of the product. Preliminary studies conducted to date have shown that the AVERSA technology is very difficult to defeat by various physical or chemical means.
The pivotal clinical study is a human abuse potential study performed to assess the impact of the potentially abuse-deterrent properties in a drug-experienced, recreational user population. The human abuse potential study is a randomized, double-blind, placebo-controlled and positive controlled crossover study comparing AVERSA Fentanyl to the currently marketed fentanyl patch which does not contain abuse-deterrent technology. The success of the human abuse potential study is based on the assessment drug liking using various instruments that are predictive of the likelihood of abuse.
Nutriband's AVERSA™ abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.
(1) Health Advances Aversa Fentanyl market analysis report 2022
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
About Kindeva
Headquartered in Woodbury, Minnesota, Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Kindeva provides unique technologies and quality services to its customers, ranging from formulation and product development to commercial manufacturing. Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, intradermal drug delivery (microneedles) and connected drug delivery. Kindeva employs approximately 1,000 people worldwide. For more information, visit www.kindevadd.com.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
RedChip Companies, Inc.
Email: NTRB@Redchip.com
Phone: 1-407-644-4256
Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751
Nutriband Inc.
Phone: 407-377-6695
Email: Support@nutriband.com
SOURCE: Nutriband Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
ToolsGroup Welcomes Supply Chain Leader Sean Elliott as Chief Executive Officer4.2.2025 15:15:00 CET | Press release
20-year industry veteran brings deep technical expertise and leadership to guide ToolsGroup's next phase of growth BOSTON, MA / ACCESS Newswire / February 4, 2025 / ToolsGroup, a global leader in supply chain and retail planning and optimization software, today announced the appointment of Sean Elliott as its new Chief Executive Officer, effective immediately. Elliott brings more than two decades of strategic leadership and technical expertise in supply chain software development and leadership to ToolsGroup. Most recently, he served as Co-CEO at Körber Supply Chain Software. At ToolsGroup, Elliott will focus on accelerating innovation, driving strategic business expansion, and strengthening its partnerships and ecosystem to deliver a best-in-class customer outcome and experience. "We are thrilled to welcome Sean to ToolsGroup," said Andrew Zbella, Principal at Accel-KKR and member of the Board of Directors. "His proven leadership, deep technical background and continued commitment to
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment4.2.2025 05:00:00 CET | Press release
With Northway Biotech's expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to stimulate hair follicle formation and promote sustained hair growth. ERLANGEN, GERMANY AND VILNIUS, LITHUANIA / ACCESS Newswire / February 4, 2025 / Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth. Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop the production process for the recombinant sCD83 protein for large-scale production, utilizing the Pichia pastoris expression system. This collab
IXOPAY Appoints Yasser Abou-Nasr as SVP of Product to Drive Execution and Scale4.2.2025 00:00:00 CET | Press release
Seasoned Fintech Leader Joins IXOPAY to Advance Product Innovation and Drive Scalable Growth in Payment Orchestration. LEHI, UT / ACCESS Newswire / February 4, 2025 / IXOPAY, a leading enterprise payment orchestration platform, announced the appointment of Yasser Abou-Nasr as SVP of Product. With over 16 years of senior product leadership in payments and fintech, Yasser joins IXOPAY to execute the company's strategic vision and scale its product offerings to meet the growing demand for seamless and secure payment solutions. Yasser brings a proven track record of driving product execution at scale, combined with deep expertise in product management, operational transformation, and the development of B2B SaaS platforms. His leadership will be instrumental in advancing IXOPAY's enterprise payment orchestration platform, enabling businesses worldwide to simplify, secure, and optimize their payment systems through scalable and flexible solutions. "Yasser's ability to execute and scale compl
Arctic Wolf and BlackBerry Announce Closing of Acquisition for Cylance3.2.2025 17:05:00 CET | Press release
WATERLOO, ON and EDEN PRAIRIE, MN / ACCESS Newswire / February 3, 2025 / Arctic Wolf® and BlackBerry Limited (NYSE:BB)(TSX:BB), two global leaders in security software and services, today announced the successful closing of the acquisition of BlackBerry's Cylance® endpoint security assets by Arctic Wolf. The two companies entered into a definitive agreement on December 15, 2024. "We are pleased to have successfully closed this pivotal transaction for BlackBerry and look forward to continuing our relationship with Arctic Wolf as a customer, as a reseller of the portfolio to our large government customers, and as a shareholder of this dynamic, growing company," said John Giamatteo, chief executive officer of BlackBerry. "Today, the launch of Aurora Endpoint Security represents a transformative step in how organizations adopt endpoint protection," said Nick Schneider, president and chief executive officer of Arctic Wolf. "By integrating Cylance's advanced AI-driven capabilities into the A
ToolsGroup Recognized as a Leader in the IDC MarketScape: Worldwide Supply Chain Planning for Spare Parts/MRO Industries 20243.2.2025 10:15:00 CET | Press release
BOSTON, MA / ACCESS Newswire / February 3, 2025 / ToolsGroup, a global leader in supply chain planning and retail optimization software, today announced it has been positioned as a Leader in the IDC MarketScape: Worldwide Supply Chain Planning for Spare Parts/MRO Industries 2024 Vendor Assessment (Doc ID #US51541424, December 2024). IDC evaluated 12 key vendors in the Spare Parts/MRO Supply Chain Planning Marketscape based on each vendor's current capabilities and future strategy. ToolsGroup was ranked #1 in current capabilities for Spare Parts/MRO supply chain planning, and an overall leader in the category. IDC specifically recommended ToolsGroup for manufacturers in all industries, especially those with large SKU offerings and/or complex distribution networks. ToolsGroup provides a uniquely effective approach to inventory optimization and demand planning leveraging probabilistic planning and decision support to manage the product line across SKUs. "We're proud to be recognized by ID
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom